Author: Kristy Licari

June 21, 2007 — ITHACA, N.Y., June 21, 2007 – Advion BioSciences,Inc., through its BioServices subsidiary, will begin offering bioanalytical immunochemistry services to the pharmaceutical and biotechnology industry starting July, 2007. This business will allow Advion to provide critical discovery and development large molecule services to the fast growing macromolecule drug pipelines underway throughout the industry. Leading the scientific team will be Dr. Esme Farley and Byron Simpson, two highly respected immunochemists with decades of combined experience in the immunoassay field and extensive knowledge with regulated bioanalysis. The facility will be located in Manassas, Virginia, a suburb of Washington, DC.

According to David Patteson, President and CEO of Advion BioSciences, “It has long been a desire to offer our clients these services and we are very pleased to have such skilled immunologists join our team”. Suburban DC was chosen as the site for this lab due to the abundance of skilled scientists in the Virginia and Maryland area, and the availability of excellent pre-existing laboratory space. Tom Kurz, President of Advion BioServices went on to state: The immunoassay service is a nice complement to our LC/MS/MS services and allows us to fully serve the bioanalytical needs for both small molecule drugs and biologics. Consistent with Advion’s reputation for scientific excellence and unparalleled service, we are committed to building an exceptional immunoassay service laboratory.

In this new laboratory, Advion will provide a full range of ligand binding assays for the development and validation of traditional and custom designed ELISA’s, RIA’s, immunoassays, immunogenicity tests, multiplexed biomarker assays, cell based assays, and flow cytometry. Immunoassay services in support of development programs will be conducted under GLP conditions with the support of Advion’s existing infrastructure. All of Advion’s pre-existing quality and regulatory processes will be implemented at this facility.

About Advion:
Founded in 1993, Advion BioSciences, Inc. is an established leader in bioanalytical science and regulatory compliance and an innovator of products for the life science industry. More information about the company can be found on its website www.advion.com.

For Advion:
Amy Boardman
Manager of Corporate Marketing Communications
Advion BioSciences, Inc.
607.266.0665 ext. 314
aboardman@advion.com

Advion held its 4th annual ASMS users meeting on June 3rd with record attendance.

Speakers from a variety of application areas gave rapid-fire ten minute presentations regarding their work with Advion’s technology.

You may request a CD of Advion’s ASMS Users Meeting presentations by emailing info@advion.com

Speakers:

Alison Ashcroft – University of Leeds
Joshua Coon – University of Wisconsin
Jonathan Josephs – Bristol-Myers Squibb
Rick King – Merck
Matthias Mann – MPI Martinsreid
Alex-James Painter – Cambridge University
Ragu Ramanathan – SPRI
Vernon Reinhold – University of New Hampshire
M. Cameron Sullards – Georgia Tech
Keqi Tang – Pacific Northwest National Laboratory

June 19, 2007– Regulatory agencies have recommended moxifloxacin, a fluoroquinolone antibiotic associated with QT prolongation, as a positive control to detect small increases in QT interval measurements. As such, Advion has recently added moxifloxacin to its list of validated non-proprietary methods for use by new and existing clients. Advion has applied this stable-labeled internal standard method in human plasma to support the study of QT prolongation of a placebo versus moxifloxacin and interference studies. Commonly used in drug-drug interaction and interference studies this recently added method is a valuable service to support anti-infective drug development efforts. It was a natural addition to Advion’s extensive non-proprietary method offering.

A full list of Advion’s validated non-proprietery methods to support drug-drug interactions or comparison studies is available on its website.

June 19, 2007– The statin class of drugs has been developed to lower cholesterol in people with risk of cardiovascular disease. Statins inhibit the enzyme HMG-CoA reductase which stimulates the LDL receptors thereby decreasing blood cholesterol levels. Advion recognizes the importance of validated LC/MS statin methods to the pharmaceutical industry in the development of cardiovascular drugs. While statins are well studied and understood, ongoing comparison studies and drug-drug research is needed on new chemical entities that are complimentary.

Advion’s offering of statin non-proprietary methods are all validated in human plasma with stable-label internal standards and include:

Amlodipine
Atorvastatin, o-hydroxyatorvastatin, p-hydroxyatorvastatin
Fenofibric acid
Lovastatin, lovastatin acid
Rosuvastatin
Simvastatin, simvastatin acid

A full list of Advion’s validated non-proprietery methods to support drug-drug interactions or comparison studies is available on its website.

June 19, 2007– The recent surge in oncology research within the pharmaceutical industry has produced a variety of oncology drugs for the treatment of a number of cancers. Treatments typically include a cocktail of prescriptions, so it is vitally important to understand the effects of co-administered drugs. Advion has a comprehensive list of validated oncology non-proprietary methods. Advion has recently added paclitaxel, its metabolite 6-hydroxypaclitaxel and gemcitabine to its offering of validated non-proprietary methods.

Advion offers a comprehensive list of validated oncology non-proprietary methods:

Bortezomib
5-Fluorouracil
Gemcitabine
Imatinib, N-desmethyl Imatinib
Paclitaxel, 6-hydroxypaclitaxel

A full list of Advion’s validated non-proprietary methods to support drug-drug interactions or comparison studies is available on its website.

April 10, 2007– Senator Charles Schumer (D-NY) held a press conference at Advion’s Catherwood Road facility on April 9th to announce his “Math for America” program which seeks to raise the quality of math and science education in America.

Read more about the press conference on the Ithaca Journal website:
http://www.theithacajournal.com/apps/pbcs.dll/article?AID=/20070410/NEWS01/704100333

April 10, 2007 — Advion BioSystems, Inc. and NanoTek, LLC announced today Advion has been appointed the distributor and support partner for NanoTek’s MinuteMan nano-scale, micro-fluidic chemistry systems. The MinuteMan represents a breakthrough approach in synthetic organic synthesis with built-in purification for discovery and batch production of biomarkers for Positron Emission Tomography (PET), pharmaceutical lead generation and bioanalytical radio labeled isotope standard synthesis. The terms of the agreement enable Advion and NanoTek to partner on a global basis and allow NanoTek to rapidly advance its product development launch plans.

According to Joe Matteo, CEO of NanoTek, “This partnership complements our skills and resources in radiochemistry and PET with Advion’s skills and resources in analytical techniques and microfabrication. The MinuteMan product has demonstrated drug synthesis performance 30 to 100 times faster than conventional technology and we will leverage the Advion sales and service network to rapidly expand our market base and product offering. Beyond the business synergies, it has been a pleasure to work with the Advion team and I expect this relationship to be a great success.”

David Patteson, CEO of Advion BioSciences, Inc. added, “We are very excited about this partnership. Advion has a rapidly growing global organization, we call on the same customer base as NanoTek, are leaders in the nano-chemistry segment with our existing product lines, and the possibility exists to integrate the product lines. The PET market is in a rapid growth phase and NanoTek has a unique solution approach. There is also substantial movement underway within clinical research institutions and pharma accounts to accelerate drug compound development using micro-fluidic solutions and PET. NanoTek gives us a substantial boost in our approach to these markets with a robust product line and an aggressive product development team who listens to, and co-develops products with customers. The combination of our Systems and bioanalytical Services business gives us an uncommon view and access into the pre-clinical/clinical PET and pharmaceutical markets as well as bioanalytical synthesis needs.

About Advion
Founded in 1993, Advion BioSciences, Inc. are pioneers in bioanalytical services and innovators of products for the life science industry. More information about the company can be found on its website www.advion.com.

About NanoTek, LLC
NanoTek is an advanced microfluidics technology company engaged in the development and production of microfluidic chemistry systems for the rapid production of Positron Emission Tomography (PET) labeled biomarkers. Our instruments provide critical tools to fuel growth in the number and diversity of imaging molecules available for PET imaging applications and pharmaceutical research. Visit us on the web at http://www.nanotek1.com.

For Advion:
Amy Boardman
Manager of Corporate Marketing Communications
607.266.9162 ext.314
aboardman@advion.com

For NanoTek, LLC:
Joe Matteo
Chief Executive Officer
865.738.1141
jmatteo@nanotek1.com

March 31, 2007 — ITHACA, N.Y., March 31, 2007 – Advion BioSciences, Inc., a leader in the life science analytical industry, announced it has completed the analysis of samples associated with the recent pet food recall. This work was done in collaboration with Cornell’s College of Veterinary Medicine, the FDA and other North American selected laboratories. Advion BioSciences was asked to act as a reference laboratory to support Cornell University’s efforts.

Aminopterin, a commonly used rat poison, was suspected of being present in certain components of the pet food. The company coordinated the efforts of its two business divisions, BioSystems and BioServices, to utilize the scientific talents at its disposal. Under the direction and coordination of Dr. Jack Henion, Chief Scientific Officer and co-founder of the company, the results were completed within 72 hours and shared with Cornell University’s College of Veterinary Medicine. Advion’s scope of work was viewed as important for the scientific mission to identify the unknown toxin in the pet food ingredients and helped form the basis of conclusions shared with the global media on March 30th. Advion confirmed the presence of melamine in wheat gluten using sophisticated commercial analytical equipment in conjunction with Advion’s systems which provided additional valuable data for the identification of melamine. Advion detected no evidence for aminopterin in any of the gluten samples.

Advion BioServices is one of the largest and most respected independent commercial bioanalytical laboratories in the world, serving the pharmaceutical and biopharmaceutical industry.

Given the broad global interest in the pet food recall, the company is strongly considering broadening its business model to analyze melamine, aminopterin and other analytes in pet food samples and pet biological samples (including blood or urine) for a fee basis. This decision will be made shortly and posted on the company’s website www.advion.com.

About Advion:
Founded in 1993, Advion BioSciences, Inc. are pioneers in bioanalytical services and innovators of products for the life science industry.

For Advion:
Amy Boardman
Advion
Manager of Corporate Marketing Communications
607.266.9162
aboardman@advion.com

March 31, 2007 — ITHACA, N.Y., March 31, 2007 As previously reported, Advion BioSciences, innovators in products for the life science industry, was called upon to collaborate with Cornell’s College of Veterinary Medicine, the FDA and other laboratories across the country to assist in analyzing samples associated with the recent pet food recall.

Following reports in the national news of a chemical named aminopterin being present in the gluten material used in components of the pet food, Advion sought to confirm the presence of aminopterin as well as identify any other foreign substances that may be present in the gluten materials. Advions efforts were directed by Dr. Jack Henion, Chief Scientific Officer. Advion’s BioServices division is a well-respected bioanalytical laboratory serving the pharmaceutical industry. Scientists from the bioanalytical laboratory worked closely with the TriVersa NanoMate application scientists to analyze the samples using LC/MS/MS.

Advion’s TriVersa Nanomate readily confirmed aminopterin in positive control standards at low part per million levels, but detected no evidence for aminopterin in any of the gluten samples reportedly associated with the pet food poisonings. During the course of these experiments, the FDA reported the presence of another chemical in the gluten called melamine. The TriVersa NanoMate system readily detected and confirmed this chemical. More information regarding this Advion product can be found at www.advion.com

About Advion:
Founded in 1993, and known as a leader in the industry, Advion BioSciences, Inc. are pioneers in bioanalytical services and innovators of products for the life science industry.

For Advion:
Amy Boardman
Manager of Corporate Marketing Communications
607.266.9162 ext. 314
aboardman@advion.com

March, 2007– Effective April 23, 2007, Advion BioSciences, Inc. and it’s subsidiaries, Advion BioServices and Advion BioSystems will relocate to one location at

19 Brown Road
Ithaca, NY 14850

The new building has been built to accomodate Advion’s growing business and to provide a more efficient work environment to serve its clients and customers.

All deliveries scheduled to arrive on or after April 23rd should be directed to the new address. Phone numbers and email addresses will remain the same. If you have any questions, please contact Advion.